PTX3/TLR4轴维持SHH型髓母细胞瘤生长并提示新的治疗脆弱性
该研究结合患者数据集转录组分析、免疫组化、RNAscope和蛋白谱检测,评估PTX3在髓母细胞瘤各亚组的表达,并在SHH-MB细胞系中进行PTX3敲低或敲除的功能研究。结果显示PTX3在SHH-MB中富集,通过TLR4依赖的IRAK1/PI3K-Akt/GSK-3/β-catenin信号 cascade 支持增殖、迁移和血管生成;遗传下调或药理学阻断PTX3-TLR4可显著减少体内肿瘤生长和血管生成。TLR4抑制剂TAK-242与标准化疗(VCC)联合在体外产生相加/协同效应,并显著延长原位SHH-MB小鼠生存。
要点
- PTX3在SHH-MB中富集并支持增殖、迁移和血管生成。
- PTX3通过TLR4依赖的IRAK1/PI3K-Akt/GSK-3/β-catenin信号通路发挥致癌作用。
- TAK-242联合VCC标准化疗在体外产生相加/协同效应并延长原位小鼠生存。
核心结论
- PTX3-TLR4信号是SHH-MB的关键致癌驱动因素和有前景的治疗脆弱性。
- 靶向该通路可增强标准化疗疗效,为机制为基础的联合策略提供依据。
研究设计与样本
- 结合患者数据集转录组分析、免疫组化、RNAscope和蛋白谱检测评估PTX3在MB亚组的表达。
- 在SHH-MB细胞系中进行PTX3敲低或敲除的功能研究,并通过皮下和原位异种移植模型测试体内相关性。
- 通过高通量药物筛选及与特异性抑制剂和标准化疗(长春新碱/顺铂/环磷酰胺;VCC)的联合研究评估治疗潜力。
主要发现
- PTX3在SHH-MB亚组中强烈富集,支持增殖、迁移和血管生成。
- PTX3激活TLR4依赖的IRAK1/PI3K-Akt/GSK-3/β-catenin信号级联。
- 遗传下调或药理学阻断PTX3-TLR4显著减少体内肿瘤生长和血管生成。
- TLR4抑制剂TAK-242在体外显著影响SHH-MB生长。
- TAK-242与VCC联合在体外产生相加/协同效应,并显著延长原位SHH-MB小鼠生存。
关键数值与推荐
- PTX3在SHH-MB亚组中富集并支持增殖、迁移和血管生成。
- PTX3激活TLR4依赖的IRAK1/PI3K-Akt/GSK-3/β-catenin信号 cascade。
- TAK-242与VCC联合在体外产生相加/协同效应并显著延长原位SHH-MB小鼠生存。
临床怎么用
- PTX3-TLR4信号可作为SHH-MB的潜在治疗靶点。
- TLR4抑制剂TAK-242联合标准化疗VCC可能增强疗效,需进一步临床研究验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Sonic hedgehog-medulloblastoma (SHH-MB) represents a biologically diverse and clinically challenging subgroup, especially in high-risk variants characterized by metastatic dissemination. Despite progress in molecular stratification, current treatments rely on intensive multimodal regimens associated with substantial long-term neurotoxicity. Identifying novel oncogenic mechanisms that can be therapeutically exploited is therefore a critical priority. METHODS: We combined transcriptomic analyses of patient datasets with immunohistochemistry, RNAscope, and protein profiling to evaluate PTX3 expression in MB subgroups. Functional studies were performed in SHH-MB cell lines following PTX3 knockdown or knockout. Effects on proliferation, migration, and angiogenesis were assessed through multiple in vitro assays. In vivo relevance was tested using subcutaneous and orthotopic xenograft models. Mechanistic insights were obtained through phospho-kinase arrays, Western blotting and GSEA. A high-throughput drug screen and combination studies with specific inhibitors and standard chemotherapy (vincristine/cisplatin/cyclophosphamide; VCC) were performed to assess therapeutic potential. RESULTS: Our results reveal that PTX3 was strongly enriched in SHH-MB subgroup, where it supported proliferation, motility, and angiogenesis. Mechanistically, PTX3 activated a TLR4-dependent IRAK1/PI3K-Akt/GSK-3/β-catenin signaling cascade. Genetic downregulation or pharmacologic blockade of PTX3-TLR4 significantly reduced tumor growth and angiogenesis in vivo. Moreover, the TLR4 inhibitor TAK-242 markedly impacted SHH-MB growth in vitro, and combination therapy of TAK-242 and VCC produced additive/synergistic effects in vitro and significantly prolonged survival in orthotopic SHH-MB-bearing mice. CONCLUSIONS: Our findings identify PTX3-TLR4 signaling as key oncogenic driver and a promising therapeutic vulnerability in SHH-MB. Targeting this pathway enhances the efficacy of standard therapy and represents a rationale for mechanism-based combination strategies. Medulloblastoma is the most common cancerous brain tumor in children. One type, called Sonic Hedgehog medulloblastoma, still needs better treatment options. We found that a protein called PTX3 helps these tumors grow by turning on signals that support cancer cell survival and blood vessel formation. When we blocked PTX3 or its partner protein, TLR4, tumor growth slowed, and standard treatment worked better, helping mice bearing medulloblastoma-like tumors live longer. These findings suggest that PTX3 could become a new treatment target. More research is needed, but this approach may help improve future therapies for children with this type of brain tumor.
引用
- Filiberti S, Tavani C, Somenza E, et al. A PTX3/TLR4 axis sustains SHH-Medulloblastoma growth and defines a new therapeutic vulnerability. Neuro Oncol. 2026. PMID: 42494116. doi:10.1093/neuonc/noag167
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。